Physician profile
Rafik Ghobrial
NPI 1326072604
$143,723.56
in general payments reported to CMS, 2019-2025
38 companies · $13K in 2025
The $13K reported for 2025 was more than what 93% of Transplant Surgery providers received nationally (typical 2025 total: $423).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,740 · 2020: $583 · 2021: $1,757 · 2022: $9,499 · 2023: $51K · 2024: $66K · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $64K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $34K · Travel and Lodging: $29K · Food and Beverage: $3,172.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $64,000.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $33,994.00 |
| Travel and Lodging | $28,979.01 |
| Food and Beverage | $3,171.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Transmedics, INC. | $76,277.47 | 2022-2024 | Organ Care System |
| Sanofi-Aventis U.S. LLC | $52,950.73 | 2024-2025 | |
| Genzyme Corporation | $4,375.00 | 2025 | |
| Sanofi US Services INC. | $2,625.00 | 2025 | |
| Gilead Sciences, INC. | $1,726.90 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $1,333.91 | 2019-2024 | Dificid, Recarbrio, Zerbaxa |
| Astrazeneca Pharmaceuticals Lp | $675.58 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $508.50 | 2021-2025 | Livtencity |
| Novartis Pharmaceuticals Corporation | $461.13 | 2019 | |
| Eisai INC. | $432.10 | 2019-2025 | |
| Abbvie INC. | $337.49 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $319.35 | 2019-2025 | Xifaxan |
| Alexion Pharmaceuticals, INC. | $213.96 | 2023-2025 | Soliris, Ultomiris |
| Fujifilm Healthcare Americas Corporation | $167.41 | 2021 | |
| Intra-Sana Laboratories | $157.76 | 2021-2022 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rafik Ghobrial listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.